Monitoring early to moderate age-related macular degeneration with AI
Part of Eyes & vision clinical trials.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 99 years old
- You have early or intermediate AMD in at least one eye (with specific retinal changes like drusen or pigment abnormalities)
- Your eyes are clear enough for imaging tests and your pupils can be dilated for the exam
- You have not had eye surgery in the past 3 months or any past treatment for wet AMD (anti-VEGF injections) in the study eye
- You do not have other eye conditions that might interfere with the study, such as advanced cataracts, uncontrolled glaucoma, or diabetic retinopathy
- You have not taken drugs that can harm the retina (like hydroxychloroquine or tamoxifen)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This study uses eye imaging and other tests to predict if early age-related macular degeneration (AMD) will progress to a more advanced stage. It aims to help doctors identify who might need closer monitoring in the future.
This study tracks how age-related macular degeneration (AMD) progresses over time and looks at factors that might affect your vision and quality of life. By participating, you'll help researchers understand more about AMD and what might predict better or worse outcomes.
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
This study looks at how well the eyes function in people with early or intermediate age-related macular degeneration (AMD). It uses imaging and vision tests to help doctors better understand the condition.
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.